ADA-friendly PDF: Treatment Guideline: Inavolisib, Palbociclib, and Fulvestrant for Hormone Receptor-Positive/HER2-negative Metastatic Breast Cancer

Treatment Guideline: Inavolisib, Palbociclib, and Fulvestrant for Hormone Receptor-Positive/HER2-negative Metastatic Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of inavolisib, palbociclib, and fulvestrant in patients with hormone receptor-positive/HER2-negative metastatic breast cancer.